Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT

F. Karl, C. Liang, R. Böttcher-Loschinski, A. Stoll, C. Flamann, S. Richter, C. Lischer, S. Völkl, B. Jacobs, M. Böttcher, R. Jitschin, H. Bruns, T. Fischer, E. Holler, W. Rösler, T. Dandekar, A. Mackensen, D. Mougiakakos

Blood (2023) 141 (13): 1626–1639.

https://doi.org/10.1182/blood.2022017267

Published: 2023

Includes: Supplemental data

Journal Articles

Safety and Efficacy of a Combination of Imatinib and Pegylated Interferon α2a (Pegasys®) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia - A Phase II Cohort Study.

Andreas Hochhaus, MD, A. Neubauer, MD, M.C. Mueller, MD, T. Fischer, MD, C. Waller, MD, T.H. Bruemmendorf, MD, T. Bostel, C. Lengerke, MD, R. Hehlmann, MD, A. Burchert, MD

Blood (2007) 110 (11): 1027.

https://doi.org/10.1182/blood.V110.11.1027.1027

Published: 2007

Journal Articles

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

C. Gambacorti-Passerini, MD, H. Kantarjian, MD, T. Bruemmendorf, MD, G. Martinelli, MD, M. Baccarani, MD, T. Fischer, MD, E.M. Pogliani, MD, B. Hewes, MD, A.D.G. Volkert, MD, N. Bardy-Bouxin, MD, J. Cortes, MD

Blood (2007) 110 (11): 473.

https://doi.org/10.1182/blood.V110.11.473.473

Published: 2007

Journal Articles

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

J. Cortes, MD, T. Bruemmendorf, MD, H. Kantarjian, MD, J. Khoury, MD, G. Rosti, MD, T. Fischer, MD, L. Tornaghi, MD, B. Hewes, MD, E.C. Martin, MD, C. Gambacorti-Passerini, MD

Blood (2007) 110 (11): 733.

https://doi.org/10.1182/blood.V110.11.733.733

Published: 2007

Journal Articles

T cell–dependent survival of CD20 + and CD20 − plasma cells in human secondary lymphoid tissue

David R. Withers, Claudia Fiorini, Randy T. Fischer, Rachel Ettinger, Peter E. Lipsky, Amrie C. Grammer

Blood (2007) 109 (11): 4856–4864.

https://doi.org/10.1182/blood-2006-08-043414

Published: 2007

Includes: Supplemental data

Journal Articles

Results of a Multicenter Phase II Trial for Older Patients with c-Kit Positive Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Using Low-Dose Ara-C (LDAC) and Imatinib.

F. Heidel, MD, J. Cortes, MD, F. Ruecker, MD, M. Kaufmann, MD, W. Aulitzky, MD, L. Letvak, MD, T. Kindler, MD, C. Huber, MD, H. Dohner, MD, H. Kantarjian, MD, T. Fischer, MD

Blood (2005) 106 (11): 1853.

https://doi.org/10.1182/blood.V106.11.1853.1853

Published: 2005

Journal Articles

Phase 1 Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML.

Francis Giles, C. Schiffer, H. Kantarjian, T. Fischer, R. Paquette, D. M. Pelov, D. J. Resta, P. S. Cohen, Y. F. Wang, R. Stone

Blood (2004) 104 (11): 262.

https://doi.org/10.1182/blood.V104.11.262.262

Published: 2004

Journal Articles

Clinical Course and Significance of the Novel FLT3-Y842C Mutation in a Patient with AML Treated with PKC412 Monotherapy.

T. Kindler, F. Breitenbuecher, S. Kasper, E. Estey, F. Giles, E. Feldman, G. Ehninger, G. Schiller, V. Klimek, S. D. Nimer, A. Gratwohl, C. Choudhary, C. Mueller-Tidow, H. Serve, H. Gschaidmeier, P. S. Cohen, C. Huber, T. Fischer

Blood (2004) 104 (11): 2537.

https://doi.org/10.1182/blood.V104.11.2537.2537

Published: 2004

Journal Articles

Mechanisms of Resistance to the FLT3-Tyrosine Kinase Inhibitor PKC412 in Patients with AML.

F. Heidel, F. Breitenbuecher, T. Kindler, F. K. Solem, B. Carius, H.-M. Thiede, P. S. Cohen, J. Roesel, E. H. Estey, E. Feldman, G. Ehninger, G. J. Schiller, V. Klimek, S. Nimer, D. DeAngelo, F. Giles, R. M. Stone, C. Huber, T. Fischer

Blood (2004) 104 (11): 454.

https://doi.org/10.1182/blood.V104.11.454.454

Published: 2004

NARROW

Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT

Safety and Efficacy of a Combination of Imatinib and Pegylated Interferon α2a (Pegasys®) in Newly Diagnosed Patients with Chronic Myelogenous Leukemia - A Phase II Cohort Study.

Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.

Efficacy and Safety of Bosutinib (SKI-606) among Patients with Chronic Phase Ph+ Chronic Myelogenous Leukemia (CML).

T cell–dependent survival of CD20 + and CD20 − plasma cells in human secondary lymphoid tissue

Results of a Multicenter Phase II Trial for Older Patients with c-Kit Positive Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Using Low-Dose Ara-C (LDAC) and Imatinib.

Phase 1 Study of PKC412, an Oral FLT3 Kinase Inhibitor, in Sequential and Concomitant Combinations with Daunorubicin and Cytarabine (DA) Induction and High-Dose Cytarabine (HDAra-C) Consolidation in Newly Diagnosed Patients with AML.

Clinical Course and Significance of the Novel FLT3-Y842C Mutation in a Patient with AML Treated with PKC412 Monotherapy.

Mechanisms of Resistance to the FLT3-Tyrosine Kinase Inhibitor PKC412 in Patients with AML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only